Amneal Pharmaceuticals (AMRX) Competitors $8.47 -0.53 (-5.89%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMRX vs. AMPH, PRGO, COLL, SVA, STML, SRPT, CTLT, RVMD, QGEN, and ITCIShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Perrigo (PRGO), Collegium Pharmaceutical (COLL), Sinovac Biotech (SVA), Stemline Therapeutics (STML), Sarepta Therapeutics (SRPT), Catalent (CTLT), Revolution Medicines (RVMD), Qiagen (QGEN), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector. Amneal Pharmaceuticals vs. Amphastar Pharmaceuticals Perrigo Collegium Pharmaceutical Sinovac Biotech Stemline Therapeutics Sarepta Therapeutics Catalent Revolution Medicines Qiagen Intra-Cellular Therapies Amphastar Pharmaceuticals (NASDAQ:AMPH) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations. Does the media refer more to AMPH or AMRX? In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 5 mentions for Amphastar Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.84 beat Amphastar Pharmaceuticals' score of 0.63 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in AMPH or AMRX? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate AMPH or AMRX? Amphastar Pharmaceuticals currently has a consensus target price of $63.00, indicating a potential upside of 41.22%. Amneal Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 18.06%. Given Amphastar Pharmaceuticals' higher possible upside, equities research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is AMPH or AMRX more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Amneal Pharmaceuticals' net margin of -6.88%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Amneal Pharmaceuticals -6.88%-346.26%4.85% Does the MarketBeat Community favor AMPH or AMRX? Amphastar Pharmaceuticals received 377 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 93.75% of users gave Amneal Pharmaceuticals an outperform vote while only 66.33% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.33% Underperform Votes19933.67% Amneal PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25% Which has more volatility and risk, AMPH or AMRX? Amphastar Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Which has stronger earnings and valuation, AMPH or AMRX? Amphastar Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$644.40M3.33$137.54M$3.0014.87Amneal Pharmaceuticals$2.39B1.10-$83.99M-$0.68-12.46 SummaryAmphastar Pharmaceuticals beats Amneal Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.62B$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-12.464.4062.6013.00Price / Sales1.10377.651,277.9088.72Price / Cash6.2751.2139.7935.27Price / Book-28.239.636.455.92Net Income-$83.99M$154.43M$119.73M$225.73M7 Day Performance-2.98%-9.46%-5.13%-1.34%1 Month Performance0.12%-7.27%-2.71%1.15%1 Year Performance86.98%28.13%31.08%24.02% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals3.1725 of 5 stars$8.47-5.9%$10.00+18.1%+93.8%$2.62B$2.39B-12.467,700Short Interest ↓AMPHAmphastar Pharmaceuticals4.88 of 5 stars$45.48-4.7%N/A-20.6%$2.19B$644.40M15.161,761Insider SellingPRGOPerrigo4.9605 of 5 stars$26.80+1.6%N/A-8.2%$3.66B$4.66B-22.919,140COLLCollegium Pharmaceutical4.1122 of 5 stars$30.18-3.9%N/A+17.8%$973.31M$566.77M13.01210SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeSTMLStemline TherapeuticsN/A$11.83flatN/A+0.0%$621.21M$43.22M-7.4492SRPTSarepta Therapeutics4.9455 of 5 stars$112.48-1.6%N/A+26.0%$10.74B$1.24B89.981,314Analyst UpgradeCTLTCatalent2.8783 of 5 stars$59.15-0.2%N/A+48.7%$10.74B$4.42B-26.1716,900Analyst UpgradeInsider SellingNews CoverageRVMDRevolution Medicines3.5596 of 5 stars$58.13-2.0%N/A+159.4%$9.78B$11.58M-16.19443QGENQiagen4.2892 of 5 stars$42.63-1.4%N/A+1.6%$9.73B$1.97B109.315,967Analyst RevisionITCIIntra-Cellular Therapies4.5093 of 5 stars$88.22-0.3%N/A+51.6%$9.35B$464.37M-101.40560Insider SellingPositive News Related Companies and Tools Related Companies AMPH Competitors PRGO Competitors COLL Competitors SVA Competitors STML Competitors SRPT Competitors CTLT Competitors RVMD Competitors QGEN Competitors ITCI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMRX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRX Stock Alerts